JP2022530989A5 - - Google Patents

Info

Publication number
JP2022530989A5
JP2022530989A5 JP2021564996A JP2021564996A JP2022530989A5 JP 2022530989 A5 JP2022530989 A5 JP 2022530989A5 JP 2021564996 A JP2021564996 A JP 2021564996A JP 2021564996 A JP2021564996 A JP 2021564996A JP 2022530989 A5 JP2022530989 A5 JP 2022530989A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
epilepsy
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530989A (ja
JP7671990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031039 external-priority patent/WO2020227097A1/en
Publication of JP2022530989A publication Critical patent/JP2022530989A/ja
Publication of JP2022530989A5 publication Critical patent/JP2022530989A5/ja
Application granted granted Critical
Publication of JP7671990B2 publication Critical patent/JP7671990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564996A 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法 Active JP7671990B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962842861P 2019-05-03 2019-05-03
US201962842855P 2019-05-03 2019-05-03
US201962842858P 2019-05-03 2019-05-03
US62/842,858 2019-05-03
US62/842,861 2019-05-03
US62/842,855 2019-05-03
US202062982858P 2020-02-28 2020-02-28
US62/982,858 2020-02-28
PCT/US2020/031039 WO2020227097A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2022530989A JP2022530989A (ja) 2022-07-05
JP2022530989A5 true JP2022530989A5 (cg-RX-API-DMAC7.html) 2023-05-11
JP7671990B2 JP7671990B2 (ja) 2025-05-07

Family

ID=73050875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564996A Active JP7671990B2 (ja) 2019-05-03 2020-05-01 Kcnt1阻害剤および使用する方法

Country Status (17)

Country Link
US (1) US20220280476A1 (cg-RX-API-DMAC7.html)
EP (2) EP4446314A3 (cg-RX-API-DMAC7.html)
JP (1) JP7671990B2 (cg-RX-API-DMAC7.html)
KR (2) KR102894020B1 (cg-RX-API-DMAC7.html)
CN (1) CN114206335B (cg-RX-API-DMAC7.html)
AU (2) AU2020267355B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022061A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002876A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016469A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP21087657A (cg-RX-API-DMAC7.html)
IL (2) IL287751B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021013422A (cg-RX-API-DMAC7.html)
PE (1) PE20220017A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430753B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112212WA (cg-RX-API-DMAC7.html)
WO (1) WO2020227097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7066871B2 (ja) 2017-12-15 2022-05-13 シロニックス リニューアブルス,インコーポレイティド 界面活性剤を形成するための反応性蒸留
WO2020014304A1 (en) 2018-07-12 2020-01-16 Sironix Renewables, Llc Surfactants from long-chain carbon-containing molecules
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11492338B2 (en) 2020-05-04 2022-11-08 Sironix Renewables, Inc. Furan surfactant compositions and methods
CN116075297A (zh) * 2020-07-06 2023-05-05 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
MX2024007031A (es) 2021-12-10 2024-11-08 Sironix Renewables Inc Ajustar sulfonacion y controlar composiciones surfactantes de oleo-furano
WO2023211855A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiophene core and methods of use
US20260199311A1 (en) * 2022-12-05 2026-07-16 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2001064644A1 (en) * 2000-03-01 2001-09-07 Nihon Bayer Agrochem K.K. Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2005066137A1 (en) * 2003-12-19 2005-07-21 Neurogen Corporation 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
WO2018204765A1 (en) * 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
WO2018227247A1 (en) * 2017-06-13 2018-12-20 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CN108517358A (zh) * 2018-04-09 2018-09-11 重庆医科大学附属第医院 一种辅助癫痫诊断的标志物及其检测试剂盒
CN120817941A (zh) * 2019-05-03 2025-10-21 普拉克西斯精密药物股份有限公司 Kcnt1抑制剂和使用方法
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11767325B2 (en) * 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
EP4110317B1 (en) * 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CN116075297A (zh) * 2020-07-06 2023-05-05 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Similar Documents

Publication Publication Date Title
JP2022531388A5 (cg-RX-API-DMAC7.html)
JP2023518838A5 (cg-RX-API-DMAC7.html)
CN115843272B (zh) Nek7激酶的抑制剂
AP1270A (en) Certain 1, 4, 5-Tri-substituted imidazole compounds useful as cytokine.
DE69724246T2 (de) Neue substituierte imidazolverbindungen
JP2023515576A5 (cg-RX-API-DMAC7.html)
AU726084C (en) Novel substituted imidazole compounds
KR100806978B1 (ko) 1,5-이치환된-3,4-디히드로-1h-피리미도[4,5-d]피리미딘-2-온 화합물 및 csbp/p38 키나제 매개된 질환의치료시 이들의 용도
JP2023532985A5 (cg-RX-API-DMAC7.html)
JP2010229154A (ja) Jakインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
JP2006506462A5 (cg-RX-API-DMAC7.html)
BR112019026955A2 (pt) derivados de di-hidro-pirrolo-piridina
JP2005514398A5 (cg-RX-API-DMAC7.html)
SI3018132T1 (en) Condensed imidazole derivatives useful as IDO inhibitors
CN106573001A (zh) 作为蛋白激酶抑制剂的氨基哒嗪酮化合物
BG106853A (bg) Антагонисти на кортикотропин освобождаващ фактор
JP2006508107A5 (cg-RX-API-DMAC7.html)
OA10904A (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and theproduction of tumor necrosis factor (tnf)
RU2015101532A (ru) Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5
AU2016325601B2 (en) 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
JP2024160326A (ja) Eaat2活性化因子およびその使用方法
RU2015101512A (ru) Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5
JP2017523202A5 (cg-RX-API-DMAC7.html)
DE60315826T2 (de) Neue verbindungen
Sedenkova et al. The first AMPA receptor negative modulators based on the tetrahydroquinazoline scaffold